Colorectal Cancer
Conditions
Keywords
Colorectal Neoplasms, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases
Brief summary
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
Interventions
DRUGNapabucasin
Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
DRUGFluorouracil
DRUGLeucovorin
DRUGIrinotecan
DRUGBevacizumab
Sponsors
Sumitomo Pharma America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written, signed consent for trial participation must be obtained from the patient appropriately in accordance with applicable ICH guidelines and local and regulatory requirements prior to the performance of any study specific procedure. 2. Must have histologically confirmed advanced CRC that is metastatic. 3. Must have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin with or without bevacizumab for metastatic disease. All patients must have received a minimum of 6 weeks of the first-line regimen that included bevacizumab (if applicable), oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or \< 6 months after the last dose of first-line therapy. 4. FOLFIRI therapy is appropriate for the patient and is recommended by the Investigator. 5. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 21 days prior to randomization. Patients with either measurable disease or non-measurable evaluable disease are eligible. 6. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 7. Must be ≥ 18 years of age. 8. For male or female patient of child bearing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for 180 days for female and male patients, of the final FOLFIRI dose. Patients who receive single agent napabucasin without FOLFIRI must agree to use contraception or take measures to avoid pregnancy during the study and for 30 days for female patients and 90 days for male patients, of the final napabucasin dose. 9. Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 5 days prior to randomization. The minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG. 10. Must have alanine transaminase (ALT) ≤ 3 × institutional upper limit of normal (ULN) \[≤ 5 × ULN in presence of liver metastases\] within 14 days prior to randomization. 11. Must have hemoglobin (Hgb) ≥ 9.0 g/dL within 14 days prior to randomization. Must not have required transfusion of red blood cells within 1 week of baseline Hgb assessment. 12. Must have total bilirubin ≤ 1.5 × institutional ULN \[≤ 2.0 x ULN in presence of liver metastases\] within 14 days prior to randomization. 13. Must have creatinine ≤ 1.5 × institutional ULN or Creatinine Clearance \> 50 ml/min (as calculated by the Cockcroft-Gault equation (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) within 14 days prior to randomization. 14. Must have absolute neutrophil count ≥ 1.5 x 10\^9/L within 14 days prior to randomization. 15. Must have platelet count ≥ 100 x 10\^9/L within 14 days prior to randomization. Must not have required transfusion of platelets within 1 week of baseline platelet assessment. 16. Patient must have adequate nutritional status with Body Mass Index (BMI) \> 18 kg/m\^2 and body weight of \> 40 kg with serum albumin \> 3 g/dL. 17. Other baseline laboratory evaluations, listed in Section 6.0, must be done within 14 days prior to randomization. 18. Patient must consent to provision of, and Investigator(s) must confirm access to and agree to submit a representative formalin fixed paraffin block of tumor tissue in order that the specific biomarker assays may be conducted. Submission of the tissue is to occur prior to randomization, unless approved by the Sponsor. Where local center regulations prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor from the block and 10-30 unstained slides of whole sections of representative tumor tissue are preferred. Where two 2 mm cores of tumor from the block are unavailable, 10-30 unstained slides of whole sections of representative tumor tissue alone are acceptable. Where no previously resected or biopsied tumor tissue exists or is available, on the approval of the Sponsor/designated CRO, the patient may still be considered eligible for the study. 19. Patient must consent to provision of a sample of blood in order that the specific correlative marker assays may be conducted. 20. Patients must be accessible for treatment and follow-up. Patients registered on this trial must receive protocol treatment and be followed at the participating center. This implies there must be reasonable geographical limits placed on patients being considered for this trial. Investigators must ensure that the patients randomized on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up. 21. Protocol treatment is to begin within 2 calendar days of patient randomization. 22. The patient is not receiving therapy in a concurrent clinical study and the patient agrees not to participate in other interventional clinical studies during their participation in this trial while on study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
Exclusion criteria
1. Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication (napabucasin or FOLFIRI) within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last dose must be observed prior to the first planned dose of study medication. Standard dose of bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per Investigator decision, for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization. Radiotherapy, immunotherapy (including immunotherapy administered for non-malignant diseaseneoplastic treatment purposes), or investigational agents within four weeks of first planned dose of study medication, with the exception of a single dose of radiation up to 8 Gy (equal to 800 RAD) with palliative intent for pain control up to 14 days before randomization. 2. More than one prior chemotherapy regimen administered in the metastatic setting. 3. Major surgery within 4 weeks prior to randomization. 4. Patients with any known brain or leptomeningeal metastases are excluded, even if treated. 5. Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI. 6. Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent (e.g. intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection). 7. Unable or unwilling to swallow napabucasin capsules daily. 8. Prior treatment with napabucasin. 9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements. 10. Known hypersensitivity to 5-fluorouracil/leucovorin 11. Known dihydropyrimidine dehydrogenase (DPD) deficiency 12. Known hypersensitivity to irinotecan 13. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) 14. Patients receiving treatment with St. John's wort or Phenytoin. 15. Patients who plan to receive yellow fever vaccine during the course of the study treatment. 16. Abnormal glucuronidation of bilirubin, known Gilbert's syndrome 17. Patients with QTc interval \> 470 milliseconds 18. For patients to be treated with a regimen containing bevacizumab: * History of cardiac disease: congestive heart failure (CHF) \> New York Heart Association (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted). * Current uncontrolled hypertension (systolic blood pressure \[BP\] \> 150 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management) as well as prior history of hypertensive crisis or hypertensive encephalopathy. * History of arterial thrombotic or embolic events (within 6 months prior to study entry) * Significant vascular disease (e.g., aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease) * Evidence of bleeding diathesis or clinically significant coagulopathy * Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to study enrollment * Proteinuria at screening as demonstrated by urinalysis with proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within 6 months * Ongoing serious, non-healing wound, ulcer, or bone fracture * Known hypersensitivity to any component of bevacizumab * History of reversible posterior leukoencephalopathy syndrome (RPLS) * History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies. 19. Patients with a history of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for \> 3 years. 20. Any active disease condition which would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy. 21. Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months) | Overall survival was defined as the time from randomization until death from any cause. Patients who are alive at the time of the interim or the final analyses or who have become lost to follow-up will be censored on the date the patient was last known to be alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months) | DCR is defined as the percentage of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. The primary estimate of DCR will be based on patients with measurable disease by RECIST 1.1 at randomization |
| Objective Response Rate (ORR) | Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months) | ORR is defined as the proportion of patients with a documented complete response and partial response (CR + PR) based on RECIST 1.1. The primary estimate for ORR will be based on patients with measurable disease by RECIST 1.1 at randomization. |
| Progression-Free Survival (PFS) | Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months) | PFS is defined as the time from randomization to the first objective documentation of disease progression per RECIST 1.1 (PD) or death, whichever comes first. |
| Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | From baseline at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1) | The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life. |
| Number of Patients With Adverse Events in the General Population | All adverse event are collected from date of signed informed consent until 30 days after protocol treatment discontinuation. Outcome followed until study discontinuation up to 4 years | All patients who have received at least one dose of either BBI-608 or FOLFIRI will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0. The incidence of adverse events will be summarized by type of adverse event and severity. |
| Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | From baseline at Time 2 (Cycle 5 Day 1), approximately 57 days and Time 4 (Cycle 9 Day 1), approximately 113 days | The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life. |
Countries
Australia, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore, South Korea, Spain, United States
Participant flow
Recruitment details
1253 participants were randomized between October 2016 and March 2019.
Pre-assignment details
Completers included patients who died, withdrew consent to survival follow up or were lost to follow up.
Participants by arm
| Arm | Count |
|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle. | 624 |
| FOLFIRI ± Bevacizumab Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle | 629 |
| Total | 1,253 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Hospice | 0 | 2 |
| Overall Study | Lost to Follow-up | 13 | 11 |
| Overall Study | Other | 3 | 8 |
| Overall Study | Withdrawal by Subject | 37 | 47 |
Baseline characteristics
| Characteristic | FOLFIRI ± Bevacizumab | Napabucasin + FOLFIRI ± Bevacizumab | Total |
|---|---|---|---|
| Age, Continuous | 59.6 years STANDARD_DEVIATION 11.14 | 60.1 years STANDARD_DEVIATION 11.17 | 59.8 years STANDARD_DEVIATION 11.16 |
| ECOG Performance Status ECOG: 0 | 332 Participants | 333 Participants | 665 Participants |
| ECOG Performance Status ECOG: 1 | 297 Participants | 291 Participants | 588 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Asian | 194 participants | 197 participants | 391 participants |
| Race/Ethnicity, Customized Black or African American | 38 participants | 29 participants | 67 participants |
| Race/Ethnicity, Customized Missing | 14 participants | 13 participants | 27 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 participants | 1 participants | 1 participants |
| Race/Ethnicity, Customized Other | 12 participants | 9 participants | 21 participants |
| Race/Ethnicity, Customized White | 370 participants | 375 participants | 745 participants |
| Region of Enrollment Australia | 24 participants | 36 participants | 60 participants |
| Region of Enrollment Belgium | 24 participants | 16 participants | 40 participants |
| Region of Enrollment Canada | 15 participants | 21 participants | 36 participants |
| Region of Enrollment China | 59 participants | 62 participants | 121 participants |
| Region of Enrollment Czechia | 19 participants | 18 participants | 37 participants |
| Region of Enrollment France | 21 participants | 20 participants | 41 participants |
| Region of Enrollment Germany | 14 participants | 12 participants | 26 participants |
| Region of Enrollment Hong Kong | 11 participants | 1 participants | 12 participants |
| Region of Enrollment Israel | 10 participants | 8 participants | 18 participants |
| Region of Enrollment Italy | 29 participants | 22 participants | 51 participants |
| Region of Enrollment Japan | 63 participants | 63 participants | 126 participants |
| Region of Enrollment Netherlands | 21 participants | 16 participants | 37 participants |
| Region of Enrollment Singapore | 9 participants | 8 participants | 17 participants |
| Region of Enrollment South Korea | 39 participants | 44 participants | 83 participants |
| Region of Enrollment Spain | 62 participants | 74 participants | 136 participants |
| Region of Enrollment United States | 209 participants | 203 participants | 412 participants |
| Sex: Female, Male Female | 254 Participants | 240 Participants | 494 Participants |
| Sex: Female, Male Male | 375 Participants | 384 Participants | 759 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 507 / 624 | 499 / 629 |
| other Total, other adverse events | 619 / 622 | 602 / 610 |
| serious Total, serious adverse events | 234 / 622 | 201 / 610 |
Outcome results
Primary
Overall Survival (OS)
Overall survival was defined as the time from randomization until death from any cause. Patients who are alive at the time of the interim or the final analyses or who have become lost to follow-up will be censored on the date the patient was last known to be alive.
Time frame: Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months)
Population: The pSTAT3 subpopulations will be defined by the results of a Clinical Trial Assay (CTA) for a specimen with an age within a defined cut-section stability (CSS) window.~A patient with positive pSTAT3 status within a defined CSS window is the one with pSTAT3 positive designated by CTA with specimen age up to 6 months at interim analysis or up to the final CSS window at final analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Overall Survival (OS) | Overall Survival (OS), General Population(GP) | 14.29 months |
| Napabucasin + FOLFIRI ± Bevacizumab | Overall Survival (OS) | Overall Survival (OS), ITT-pSTAT3(+) | 13.17 months |
| FOLFIRI ± Bevacizumab | Overall Survival (OS) | Overall Survival (OS), General Population(GP) | 13.83 months |
| FOLFIRI ± Bevacizumab | Overall Survival (OS) | Overall Survival (OS), ITT-pSTAT3(+) | 12.12 months |
Comparison: General populationp-value: 0.362995% CI: [0.854, 1.117]Log Rank
Comparison: activated signal transducers and activators of transcription 3 (pSTAT3)-positive (pSTAT3(+)) Subpopulation patientsp-value: 0.378295% CI: [0.797, 1.179]Log Rank
Secondary
Disease Control Rate (DCR)
DCR is defined as the percentage of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. The primary estimate of DCR will be based on patients with measurable disease by RECIST 1.1 at randomization
Time frame: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Population: Analysis population of DCR will be based on patients with measurable disease by RECIST 1.1 at randomization. A patient with positive pSTAT3 status within a defined CSS window is the one with pSTAT3 positive designated by CTA with specimen age up to 6 months at interim analysis or up to the final CSS window at final analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Disease Control Rate (DCR) | Disease Control Rate (DCR), General Population(GP) | 69.6 percentage of participants |
| Napabucasin + FOLFIRI ± Bevacizumab | Disease Control Rate (DCR) | Disease Control Rate (DCR), ITT-pSTAT3(+) | 67.2 percentage of participants |
| FOLFIRI ± Bevacizumab | Disease Control Rate (DCR) | Disease Control Rate (DCR), General Population(GP) | 69.1 percentage of participants |
| FOLFIRI ± Bevacizumab | Disease Control Rate (DCR) | Disease Control Rate (DCR), ITT-pSTAT3(+) | 70.3 percentage of participants |
Comparison: General populationp-value: 0.479795% CI: [-4.9, 5.2]Cochran-Mantel-Haenszel
Comparison: activated signal transducers and activators of transcription 3 (pSTAT3)-positive (pSTAT3(+)) Subpopulation patientsp-value: 0.78395% CI: [-11, 4.7]Z test
Secondary
Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life.
Time frame: From baseline at Time 2 (Cycle 5 Day 1), approximately 57 days and Time 4 (Cycle 9 Day 1), approximately 113 days
Population: The number of patients is with at least one valid assessment at each analysis window
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Global Health status at Time 2 (Cycle 5 Day 1). General Population | -7.07 score on a scale | Standard Deviation 21.936 |
| Napabucasin + FOLFIRI ± Bevacizumab | Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Global Health status at Time 4 (Cycle 9 Day 1). General Population | -7.70 score on a scale | Standard Deviation 21.932 |
| FOLFIRI ± Bevacizumab | Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Global Health status at Time 2 (Cycle 5 Day 1). General Population | -5.45 score on a scale | Standard Deviation 20.607 |
| FOLFIRI ± Bevacizumab | Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Global Health status at Time 4 (Cycle 9 Day 1). General Population | -5.58 score on a scale | Standard Deviation 21.59 |
Secondary
Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
The Quality of Life (QoL) of patients will be assessed using European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ-C30) (EORTC QLQ-30) while the patient remains on study treatment (FOLFIRI with or without BBI-608). EORTC QLQ-30 is used to assess the overall quality of life in cancer patients using 28 questions with a 4 point scale. (1 'Not at all' to 4'Very Much'); 2 questions use a 7-point sale (1 'Very Poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; higher overall score = better quality of life.
Time frame: From baseline at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1)
Population: The number of patients is with at least one valid assessment at each analysis window.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Physical Functioning at Time 2 (Cycle 5 Day 1). General Population | -5.86 QOL score on a scale | Standard Deviation 17.204 |
| Napabucasin + FOLFIRI ± Bevacizumab | Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Physical Functioning at Time 4 (Cycle 9 Day 1). General Population | -6.37 QOL score on a scale | Standard Deviation 15.095 |
| FOLFIRI ± Bevacizumab | Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Physical Functioning at Time 2 (Cycle 5 Day 1). General Population | -3.94 QOL score on a scale | Standard Deviation 14.472 |
| FOLFIRI ± Bevacizumab | Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1). | Mean Change From Baseline for Physical Functioning at Time 4 (Cycle 9 Day 1). General Population | -4.22 QOL score on a scale | Standard Deviation 15.023 |
Secondary
Number of Patients With Adverse Events in the General Population
All patients who have received at least one dose of either BBI-608 or FOLFIRI will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0. The incidence of adverse events will be summarized by type of adverse event and severity.
Time frame: All adverse event are collected from date of signed informed consent until 30 days after protocol treatment discontinuation. Outcome followed until study discontinuation up to 4 years
Population: All patients who received at least 1 dose of study drug (BBI-608 and/or FOLFIRI) with treatment assignment designated according to the actual study treatment received. Adverse event is analyzed in the SAS population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Number of Patients With Adverse Events in the General Population | Number of Patients with Adverse Events in the General Population | 619 Participants |
| Napabucasin + FOLFIRI ± Bevacizumab | Number of Patients With Adverse Events in the General Population | Number of Patients with Adverse Events in the pSTAT3(+) Subpopulation | 275 Participants |
| FOLFIRI ± Bevacizumab | Number of Patients With Adverse Events in the General Population | Number of Patients with Adverse Events in the General Population | 602 Participants |
| FOLFIRI ± Bevacizumab | Number of Patients With Adverse Events in the General Population | Number of Patients with Adverse Events in the pSTAT3(+) Subpopulation | 266 Participants |
Secondary
Objective Response Rate (ORR)
ORR is defined as the proportion of patients with a documented complete response and partial response (CR + PR) based on RECIST 1.1. The primary estimate for ORR will be based on patients with measurable disease by RECIST 1.1 at randomization.
Time frame: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Population: Analysis set for ORR will be based on patients with measurable disease by RECIST 1.1 at randomization.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Objective Response Rate (ORR) | Objective Response Rate (ORR), General Population(GP) | 13.8 percentage of participants |
| Napabucasin + FOLFIRI ± Bevacizumab | Objective Response Rate (ORR) | Objective Response Rate (ORR), ITT-pSTAT3(+) | 11.9 percentage of participants |
| FOLFIRI ± Bevacizumab | Objective Response Rate (ORR) | Objective Response Rate (ORR), General Population(GP) | 14.6 percentage of participants |
| FOLFIRI ± Bevacizumab | Objective Response Rate (ORR) | Objective Response Rate (ORR), ITT-pSTAT3(+) | 13.9 percentage of participants |
Comparison: General populationp-value: 0.677695% CI: [-4.8, 3]Cochran-Mantel-Haenszel
Comparison: activated signal transducers and activators of transcription 3 (pSTAT3)-positive (pSTAT3(+)) Subpopulation patientsp-value: 0.751395% CI: [-7.7, 3.7]Z test
Secondary
Progression-Free Survival (PFS)
PFS is defined as the time from randomization to the first objective documentation of disease progression per RECIST 1.1 (PD) or death, whichever comes first.
Time frame: Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Population: The pSTAT3 subpopulations will be defined by the results of a Clinical Trial Assay (CTA) for a specimen with an age within a defined cut-section stability (CSS) window.~A patient with positive pSTAT3 status within a defined CSS window is the one with pSTAT3 positive designated by CTA with specimen age up to 6 months at interim analysis or up to the final CSS window at final analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab | Progression-Free Survival (PFS) | Progression-Free Survival (PFS), General Population(GP) | 5.55 months |
| Napabucasin + FOLFIRI ± Bevacizumab | Progression-Free Survival (PFS) | Progression-Free Survival (PFS) , ITT-pSTAT3(+) | 5.39 months |
| FOLFIRI ± Bevacizumab | Progression-Free Survival (PFS) | Progression-Free Survival (PFS), General Population(GP) | 5.62 months |
| FOLFIRI ± Bevacizumab | Progression-Free Survival (PFS) | Progression-Free Survival (PFS) , ITT-pSTAT3(+) | 5.55 months |
Comparison: General populationp-value: 0.730795% CI: [0.917, 1.18]Log Rank
Comparison: activated signal transducers and activators of transcription 3 (pSTAT3)-positive (pSTAT3(+)) Subpopulation patientsp-value: 0.743495% CI: [0.883, 1.283]Log Rank